Fredun Pharmaceuticals has informed that the Board of Directors of the Company at its meeting held today, Wednesday, August 05, 2026 has inter-alia, considered, adopted and approved following items of business: In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the quarter ended 30th June, 2026 along with the Limited Review Report as issued by R.H. Nisar & Co, Statutory Auditor of the Company; copies of which are attached hereunder; In furtherance to the intimation filed by the Company dated July 30, 2026; the trading window for trading in securities of the Company by insiders closed on July 01, 2026 till the end of 48 hours after the declaration of outcome of this Board Meeting. The Board Meeting commenced at 10:30 a.m. and concluded at 11:20 a.m.
The above information is a part of company’s filings submitted to BSE.
